Press Releases
View printer-friendly version << Back
Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Presentation details: | |
Date: | |
Time: | |
Webcast: | A live and archived webcast of the presentation will be available at (click here) or on the Company’s website (click here) |
In addition, management will be participating in one-on-one meetings with investors who are registered to attend the conference.
About Avadel Pharmaceuticals plc:
About FT218
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. In March of 2020, the Company completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the
Contacts:
Investor Contacts |
Chief Financial Officer |
Phone: (636) 449-1843 |
Email: tmchugh@avadel.com |
Phone: (212) 915-2564 |
Email: tim@lifesciadvisors.com |
Media Contact |
Phone: (646) 970-4688 |
Email: pbursey@lifescicomms.com |
Source: Avadel Pharmaceuticals plc